CD4 and cancer: Since activated Treg cells may confer resistance to checkpoint inhibitors, the signaling pathway analysis of CD4+ T cells in TIL or in blood samples of cancer patients may enable an improved prediction and monitoring of response to checkpoint inhibitor therapy.